| Base case value | Low value | High Value | ICER/QALY gained low | ICER/QALY gained high |
---|---|---|---|---|---|
Acenocoumarol monitoring maintenance visits | 3.00 | 1.00 | 5.00 | €8,635 | Riv. Dom. |
Subsequent discontinuation rate riva | 0.04 | 0.00 | 0.09 | €7,630 | Riv. Dom. |
Utility decrement: stable on acenocoumarol therapy | 0.95 | 0.92 | 1.00 | Riv. Dom. | Riv. Dom. |
Discontinuation rate riva | 0.09 | 0.00 | 0.54 | €390 | Riv. Dom. |
Subsequent discontinuation rate acenocoumarol | 0.04 | 0.00 | 0.06 | Riv. Dom. | €942 |
Discontinuation rate acenocoumarol | 0.08 | 0.00 | 0.31 | Riv. Dom. | €3311 |
Myocardial infarction RR for rivaroxaban | 0.81 | 0.63 | 1.06 | Riv. Dom. | Riv. Dom. |
Rivaroxaban effectiveness | 1.00 | 0.75 | 1.25 | Riv. Dom. | Riv. Dom. |
Stroke RR for riva | 0.94 | 0.75 | 1.17 | Riv. Dom. | Riv. Dom. |
Acenocoumarol monitoring cost – follow | 22.00 | 17.69 | 26.31 | €228 | Riv. Dom. |
Acenocoumarol monitoring cost-initiation | 32 | 25.73 | 38.27 | Riv. Dom. | Riv. Dom. |
Transport need (% of patients) | 50% | 0% | 100% | €10,388 | Riv. Dom. |
Other therapy monitoring visits | 0.25 | 0 | 1 | Riv. Dom. | Riv. Dom. |